Description

QuidelOrtho Corporation’s Margin Recovery Meets China, Respiratory & Cash Flow Headwinds !

The second quarter of 2026 results for QuidelOrtho Corporation revealed a mixed performance shaped by ongoing challenges in China and a softer respiratory testing environment, while its broader business demonstrated resilience across regions and core franchises. Total company revenue grew modestly by 2% on a constant currency basis, with a notable 23% decline in China driven by uncertainty related to evolving in vitro diagnostics (IVD) pricing guidelines, which have prompted customers to reduce inventories in anticipation of final regulations. This contraction in China, a significant market for the company, substantially impacted overall growth and introduced near-term demand uncertainties due to shifting healthcare policies and reimbursement environments. Excluding China, revenue showed stronger momentum, increasing 6% year-over-year, supported by 9% growth in labs revenue, 5% in Immunohematology, and 9% expansion in the Triage point-of-care segment.